Malignant neoplasm of bronchus and lung
Chapter 2:Neoplasms
ICD-10 C34 is a billable code used to indicate a diagnosis of malignant neoplasm of bronchus and lung.
Malignant neoplasms of the bronchus and lung encompass a variety of lung cancers, primarily including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). These cancers arise from the epithelial cells of the lung and bronchial tubes, often linked to risk factors such as smoking, environmental pollutants, and genetic predispositions. Symptoms may include persistent cough, hemoptysis, chest pain, and weight loss. Diagnosis typically involves imaging studies such as chest X-rays and CT scans, followed by biopsy for histological confirmation. Staging is crucial for treatment planning and is based on the TNM classification system, which assesses tumor size (T), lymph node involvement (N), and distant metastasis (M). Molecular markers, such as EGFR mutations and ALK rearrangements, play a significant role in targeted therapies. Treatment algorithms may include surgery, chemotherapy, radiation therapy, and immunotherapy, tailored to the cancer type, stage, and patient health status.
Detailed pathology reports, staging information, treatment plans, and follow-up notes.
Initial diagnosis of lung cancer, staging workup, treatment planning, and management of treatment side effects.
Ensure accurate documentation of histological type and staging to support coding.
Pulmonary function tests, imaging studies, and smoking history documentation.
Evaluation of lung nodules, management of lung cancer-related respiratory issues, and pre-operative assessments.
Documenting the patient's smoking history and respiratory symptoms is crucial for accurate coding.
Used in patients with lung cancer presenting with pleural effusion.
Document the indication for the procedure and any imaging guidance used.
Pulmonology specialists should ensure accurate coding based on the patient's lung cancer status.
Used for staging or resection of lung tumors.
Detailed operative report and pathology results are necessary.
Oncology specialists must document the extent of resection and any complications.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of cases, while small cell lung cancer (SCLC) is less common but more aggressive. NSCLC is typically treated with surgery, chemotherapy, and targeted therapies, whereas SCLC is usually treated with chemotherapy and radiation.
Smoking history is crucial in coding lung cancer as it is a significant risk factor. Accurate documentation of smoking status can impact treatment decisions and is often required for insurance reimbursement.
